New application of triazolo[4,5-d]pyrimidine derivatives
By combining triazolo[4,5-d]pyrimidine derivatives with detectable markers or signal amplifiers, specific diagnosis and prediction of deep bacterial infections are achieved, solving diagnostic difficulties and tracers in the prior art Unspecific problems provide early diagnostic and predictive capabilities.
Patent Information
- Application Number
- CN202080028379.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-07-25
- Filing Date
- 2020-07-22
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-07-22
AI Technical Summary
The prior art is difficult to effectively diagnose and predict deep bacterial infections in host mammals, especially in the early stages, and existing tracers are not specific to bacterial infections and cannot distinguish infection from sterile inflammation or cancer.
Using triazolo[4,5-d]pyrimidine derivatives as tracers, through their combination with detectable markers or signal amplifiers, targeted imaging and diagnosis of bacterial infections can be achieved, which can be used quickly and non-invasively. It is divided into infection and sterile inflammation or cancer.
Triazolo[4,5-d]pyrimidine derivatives can specifically target bacterial infections, provide early diagnosis and prediction capabilities, reduce misdiagnosis and mistreatment of bacterial infections, and provide reliable demonstrations for in vivo and in vitro applications. Tracker solutions.
Smart Images

Figure CN113677684B_ABST
Abstract
Description
Field of the Invention
[0001] The present invention relates to triazolo[4,5-d]pyrimidine derivatives for use in the in vivo prognosis and / or diagnosis of bacterial infections, particularly deep-seated bacterial infections, in a host mammal. The present invention also relates to methods for imaging said bacterial infections and the use of triazolo[4,5-d]pyrimidine derivatives in the in vitro prognosis and / or diagnosis of bacterial infections. Background Art
[0002] Bacterial infections are a major cause of morbidity and mortality, particularly when deep-seated infections are present.
[0003] Deep infection is difficult to diagnose from other causes of inflammation. Current practice relies on biopsy, blood, urine sample analysis, or radiological techniques, such as magnetic resonance imaging (MRI), X-ray, ultrasound (US), X-ray computed tomography (CT) etc., which allow localization of infection and detection of morphological changes relevant to infection, host response or both. Unfortunately, such morphological changes may not be distinguished from inflammation or cancer tumors. In addition, these morphological changes may not be detected in the early stages of infection, and remain nonspecific when they exist.
[0004] Tracers labeled with a radioactive element, then called radiolabels, can also be used to identify deep-seated infections. Radiolabels (also called radiotracers) can be detected by nuclear imaging techniques such as single photon emission computed tomography (SPECT) or positron emission tomography (PET). Examples of radiotracers are 18 F-fluorodeoxyglucose PET, 67 Ga-citrate SPECT or radiolabeled leukocyte SPECT, but they are not specific for bacterial infection and cannot distinguish infection from sterile inflammation or cancer.
[0005] Therefore, there is an urgent need in the art for a new tracer for prognosis or diagnosis of bacterial infection (particularly deep infection) in a host mammal. A tracer that will be specific and sensitive to bacteria but is non-toxic, affordable, widely available, and easy and rapid to prepare is needed. Summary of the invention
[0006] We have surprisingly found that triazolo[4,5-d]pyrimidine derivatives or compositions thereof can be used as tracers for prognosis and / or diagnosis of bacterial infection in a host mammal. Triazolo[4,5-d]pyrimidine derivatives have the advantage of rapidly and non-invasively targeting early stage infection and thus distinguishing infection from sterile inflammation or cancer. Triazolo[4,5-d]pyrimidine derivatives also have the advantage of diagnosing or prognosing a broad spectrum of bacteria belonging to Gram-positive or Gram-negative species.
[0007] Triazolo[4,5-d]pyrimidine derivatives can be taken up by bacterial cells and can therefore be used as tracers for the prognosis and / or diagnosis of bacterial infections in vivo or in vitro. DETAILED DESCRIPTION
[0008] In one aspect, the present invention provides a triazolo[4,5-d]pyrimidine derivative of formula (I) for use in the in vivo prognosis and / or diagnosis of a bacterial infection in a host mammal.
[0009] In another aspect, the present invention provides the use of a triazolo[4,5-d]pyrimidine derivative of formula (I) in the prognosis and / or diagnosis of bacterial infection in vitro.
[0010] The term "bacterial infection" refers to, for example, pneumonia, septicemia, endocarditis, osteomyelitis, meningitis, urinary tract, skin and soft tissue infections, but also to infective endocarditis associated with cardiac implants, prosthetic valve endocarditis or periprosthetic joint infections that occur in 1% or 2% of joint replacement surgeries.
[0011] Bacterial infections, for example, can be caused by Staphylococcus aureus (S. aureus), Staphylococcus epidermidis (S. epidermidis), Enterococcus faecalis (E. faecalis), Enterococcus faecium (E. faecium), methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE), glycopeptide intermediate Staphylococcus aureus (GISA), coagulase-negative staphylococci (CoNS), vancomycin-resistant enterococci (VRE), beta-hemolytic Streptococcus agalactiae (Beta-hemolytic Streptococcus agalactiae agalactiae (group B Streptococcus, GBS) or one or more of other streptococci belonging to Gram-positive bacteria, or caused by one or more of Acinetobacter baumannil, Pseudomonas aeruginosa, carbapenem-resistant Pseudomonas aeruginosa, Enterobacteriaceae, and third-generation cephalosporin-resistant Enterobacteriaceae belonging to Gram-negative bacteria (Klebsiella pneumonia, Escherichia coli, Enterobacter spp., Serratia spp., Proteus spp., Providentia spp., and Morganella spp.).
[0012] As used herein, the term diagnosis refers to the identification of a bacterial infection in a host mammal.
[0013] As used herein, the term prognosis refers to determining the intensity of a bacterial infection in a host mammal at any stage, particularly in the early stages.
[0014] As used herein, the term host mammal preferably refers to a human, but also refers to animals.
[0015] In a particular embodiment, the triazolo[4,5-d]pyrimidine derivative of formula (I) comprises a detectable label.
[0016] In another particular embodiment, the triazolo[4,5-d]pyrimidine derivative of formula (I) is conjugated to a detectable label.
[0017] As used herein, the term "detectable marker" refers to any type of label, which is detectable and thus allows the presence of a triazolo[4,5-d]pyrimidine derivative to be determined:
[0018] - directly, for example as a radiolabeled triazolo[4,5-d]pyrimidine derivative, wherein for example one atom of the derivative has been replaced by a radioisotope label selected from the group consisting of: 2 H. 3 H, 13 F. 18 F. 19 F. 11 C. 13 C. 14 C. 75 Br, 76 Br, 120 I. 123 I. 124 I. 125 I. 131 I. 15 O. 13 N. 78 Br, etc.; preferably, one halogen atom is selected from 13 F. 18 F. 19 F. 75 Br, 76 Br, 120 I. 123 I. 124 I. 125 I. 131 I. 78 A radioisotope substitution of Br, etc.;
[0019] - or directly as a radiolabeled triazolo[4,5-d]pyrimidine derivative, wherein the derivative can be combined with a radiolabel such as 99 Tc, 63 Ga, 67 Ga, 111 In and other composites;
[0020] - or indirectly, for example via a transporter comprising a signal amplifier. The triazolo[4,5-d]pyrimidine derivative is then chemically bound to the transporter and the derivative can be considered a sensor of bacterial infection.
[0021] As used herein, the term "signal amplifier" refers to any agent that will amplify the return signal at a bacterially infected tissue or implant.
[0022] The signal amplifier can, for example, enhance the reflection, refraction, scattering, transmission or attenuation of ultrasound waves at bacteria-infected tissues or implants in US imaging tomography; or enhance the resonance or different hydrogen arrangements in response to radio frequency pulses emitted by a magnetic field at bacteria-infected tissues or implants in magnetic resonance imaging; or enhance the proportion of X-rays absorbed or scattered at bacteria-infected tissues or implants in X-ray computed tomography (CT).
[0023] As used herein, the term "transporter" refers to a body that acts as a signal amplifier or in which a signal amplifier can be incorporated, such as a micelle, microsphere, liposome, polymer particle, nanosphere, nanosuspension, nanoemulsion, nanocapsule, etc.
[0024] Triazolo[4,5-d]pyrimidine derivatives comprising a detectable marker via a radioactive isotope, or triazolo[4,5-d]pyrimidine derivatives bound to a detectable marker via a complex with the detectable marker or via a transporter comprising the detectable marker, are hereinafter also referred to as detectable triazolo[4,5-d]pyrimidine derivatives.
[0025] In a particular embodiment, the detectable label is a signal amplifier that is indirectly associated with the triazolo[4,5-d]pyrimidine derivative for use in a detection method that will rely on the properties of the label.
[0026] Triazolo[4,5-d]pyrimidine derivatives can be combined with signal amplifiers such as gadolinium (e.g. 64In some embodiments, the present invention relates to a nanoparticle of Mn-SPIO, which is a ferromagnetic compound that can enhance magnetic resonance imaging. The Gd chelate can be an ionic (e.g., meglumine or sodium salt) or non-ionic signal amplifier. Iron oxide (iron oxide) can also be used as a signal amplifier for MRI. For example, superparamagnetic iron oxide nanoparticles doped with manganese can be used to form ultrasensitive MRI contrast agents. Then, such Mn-SPIO nanoparticles are self-assembled in micelles into clusters that will be detectable by MRI. Other signal amplifiers for MRI are, for example, manganese chelates, iron-platinum (FePt) alloy nanocrystals, manganese ferrite (MnO-Fe2O3) nanocrystals or other metal-doped iron oxide nanoparticles such as Co-Fe2O3 and NiO-Fe2O3.
[0027] The triazolo[4,5-d]pyrimidine derivatives can also be associated with signal amplifiers such as microbubbles for contrast-enhanced ultrasound imaging (US).
[0028] The triazolo[4,5-d]pyrimidine derivatives can also be associated with a signal amplifier (also called a contrast agent) containing iodine or barium for use in X-ray computed tomography (CT). The contrast agent should increase the absolute CT attenuation difference between the target bacterial infection and the surrounding tissue. An example of a suitable contrast agent for X-ray computed tomography is iohexol (Omnipaque TM , GE Healthcare); iopromide (Ultravist TM , Bayer Healthcare); iodixanol (Visipaque TM , GE Healthcare); ioxaglate (Hexabrix TM , Mallinckrodt Imaging); iothalamate (Cysto-Conray II TM , Mallinckrodt Imaging); and iopamidol (Isovue TM , Bracco Imaging).
[0029] In another particular embodiment, the detectable label is an isotope, which allows the use of triazolo[4,5-d]pyrimidine derivatives as tracers in detection methods that will rely on the properties of the label. Thus, triazolo[4,5-d]pyrimidine derivatives comprising at least one detectable isotope can be detected by using beta, gamma, positron or X-ray imaging, where for example the beta or gamma irradiation is provided by the relevant isotope and detected at an appropriate wavelength.
[0030] Triazolo[4,5-d]pyrimidine derivatives containing at least one detectable isotope can be used, for example, with magnetic resonance spectroscopy (MRS) or magnetic resonance imaging (MRI), X-ray computed tomography (CT), positron emission tomography (PET) and single emission computed tomography (SPECT).
[0031] Detectable triazolo[4,5-d]pyrimidine derivatives can be obtained by isotopic characterization using well-known organic chemistry techniques. 19 F or 13 C or a combination thereof is detected for MRS / MRI.
[0032] Other detectable triazolo[4,5-d]pyrimidine derivatives can also be selected from 19 F. 11 C. 75 Br, 76 Br or 120 Isotopes of I or a combination thereof are detected for use in PET technology.
[0033] Other detectable triazolo[4,5-d]pyrimidine derivatives can also be selected from 18 F or 11 C or a combination of isotopes thereof are detected for PET in vivo imaging and can be used as in Bengt Prepared as described in Acta Chemica Scandinavia, 53: 651-669 (1999) or the journal of Nuclear Medicine 58(7): 1094-1099 (2017) AMJ Paans in https: / / cds.cern.ch / record / 1005065 / files / p363.pdf.
[0034] Other detectable triazolo[4,5-d]pyrimidine derivatives can be 123 I and 131 I is detected for SPECT imaging and can be prepared as described by Kulkarni, Int. J. Rad. Appl. & Inst (part B) 18:647 (1991).
[0035] Other detectable triazolo[4,5-d]pyrimidine derivatives can also be detected using Tc-99m ( 99m Tc), 123 I and 111IN is detected for SPECT imaging. The corresponding radiolabeled triazolo[4,5-d]pyrimidine derivatives can be readily prepared by a person skilled in the art by techniques well known in the art and described by Zhuang in Nuclear Medicine & Biology 26(2):217-24 (1999) or by Kulkarni in Nuclear Medicine & Biology 18(6):647-654 (1991) or in Technical Report 466 published by the International Atomic Energy Agency in 2008.
[0036] Triazolo[4,5-d]pyrimidine derivatives in which one or more atoms are replaced by a radionuclide or isotope can be used as radiotracers to test cells, tissues or fluids from a host mammal and identify the presence and significance of bacterial infection in the host (eg, at the surface of a prosthetic valve).
[0037] As used herein, the term "host mammal" preferably refers to a human, but also refers to animals.
[0038] The term triazolo[4,5-d]pyrimidine derivative refers to a compound of the following formula (I):
[0039]
[0040] Where R 1 is C optionally substituted by one or more halogen atoms 3-5 Alkyl; R 2 is phenyl optionally substituted by one or more halogen atoms; R 3 and R 4 Each is hydroxy; R is XOH, wherein X is CH2, OCH2CH2 or a bond;
[0041] or a pharmaceutically acceptable salt or solvate thereof, or a solvate thereof or a solvate of such a salt, provided that when X is CH2 or a bond, R 1 is not propyl; when X is CH2 and R 1 When it is CH2CH2CF3, butyl or pentyl, R 2 The phenyl group at the position must be substituted by fluorine; when X is OCH2CH2 and R 1 When it is propyl, R 2 The phenyl group at each position must be substituted by fluorine.
[0042] Whether alone or as part of another group, an alkyl group is straight-chain and fully saturated.
[0043] In some embodiments, R1 may represent C optionally substituted by one or more fluorine atoms 3-5 Preferably, R 1 It is 3,3,3-trifluoropropyl, butyl or propyl.
[0044] In some embodiments, R 2 It may represent a phenyl group or a phenyl group substituted by one or more halogen atoms. 2 is phenyl substituted by one or more fluorine atoms. Most preferably, R 2 It is 4-fluorophenyl or 3,4-difluorophenyl.
[0045] In some embodiments, R may represent XOH, wherein X is CH2, OCH2CH2 or a bond; preferably, R is OH or OCH2CH2OH.
[0046] The most preferred triazolo[4,5-d]pyrimidine derivatives are those wherein R 2 represents 4-fluorophenyl or 3,4-difluorophenyl and / or a compound of formula (I) in which R represents OCH2CH2OH.
[0047] Triazolo[4,5-d]pyrimidine derivatives are well-known compounds. They can be obtained according to the method described in US Pat. No. 6,525,060, col. 3, line 26 to col. 8, line 14, which is incorporated herein by reference.
[0048] Preferred triazolo[4,5-d]pyrimidine derivatives are those in which R represents OH or OCH2CH2OH and / or R 2 It represents a derivative of 4-fluorophenyl or 3,4-difluorophenyl.
[0049] The most preferred triazolo[4,5-d]pyrimidine derivatives are: (1R-(1α,2α,3β(1R*,2*),5β))-3-(7-((2-(3,4-difluorophenyl)cyclopropyl)amino)-5-((3,3,3-trifluoropropyl)thio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(hydroxy)cyclopentane-1,2-diol;
[0050] (1S-(1α,2α,3β(1R*,2*),5β))-3-(7-((2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol;
[0051] (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol;
[0052] (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(4-fluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol)
[0053] or a pharmaceutically acceptable salt or solvate thereof, or a solvate thereof or a solvate of such a salt.
[0054] The most preferred triazolo[4,5-d]pyrimidine derivative for use in prognosis and / or diagnosis is (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol as defined in formula (II) (and also referred to hereinafter as Triafluocyl):
[0055]
[0056] or a pharmaceutically acceptable salt or solvate thereof, or a solvate thereof or a solvate of such a salt.
[0057] Another most preferred triazolo[4,5-d]pyrimidine derivative for use in prognosis and / or diagnosis is (1S,2R,3S,4R)-4-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-1,2,3-cyclopentanetriol as defined in formula (III) (and also referred to as Fluometacyl):
[0058]
[0059] or a pharmaceutically acceptable salt or solvate thereof, or a solvate thereof or a solvate of such a salt.
[0060] In some embodiments, one atom of the triazolo[4,5-d]pyrimidine derivative of formula (I) is selected from the group consisting of: 3 H. 13 F. 18 F. 19 F. 11 C.13 C. 14 C. 75 Br, 76 Br, 120 I. 123 I. 124 I. 125 I. 131 I. 15 O. 13 N. 78 Br.
[0061] In some embodiments, one halogen substituent of the triazolo[4,5-d]pyrimidine derivative of formula (I) may be 18 F or 123 I.
[0062] In some embodiments, one halogen substituent of the triazolo(4,5-d)pyrimidine derivative of formula (I) may be 18 F.
[0063] In some embodiments, R in the triazolo[4,5-d]pyrimidine derivative of formula (I) 2 A halogen substituent of may be 18 F.
[0064] In another aspect, the present invention provides a pharmaceutical composition comprising a triazolo[4,5-d]pyrimidine derivative of formula (I) and a pharmaceutical additive for use in in vivo diagnosis and / or prognosis of bacterial infection in a host mammal;
[0065] In yet another aspect, the present invention provides use of a pharmaceutical composition comprising a triazolo[4,5-d]pyrimidine derivative of formula (I) and a pharmaceutically acceptable additive in the prognosis and / or diagnosis of bacterial infection in vitro.
[0066] The pharmaceutical composition may be a dry powder or a liquid composition having physiological compatibility. In some embodiments, the pharmaceutical additive may be an auxiliary substance, a preservative, a solvent and / or a viscosity modifier.
[0067] Solvent means any suitable physiologically compatible solvent, such as, for example, water, saline or any other physiological solution, ethanol, glycerol, oil (such as vegetable oil) or mixtures thereof. Viscosity modifier means, for example, sugar polymers (such as carboxymethylcellulose), polysaccharides (such as saccharin) and the like.
[0068] In some embodiments, triazolo[4,5-d]pyrimidine derivatives or pharmaceutical compositions thereof containing a detectable label and used as radiotracers can be administered locally or systemically by inhalation, ingestion or injection at a dose relevant to the selected imaging device. Administration can be oral, parenteral, topical, rectal, nasal, vaginal administration.
[0069] Parenteral means subcutaneous, intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular and the like.
[0070] Dosage levels administered to the host mammal depend on its age, weight, general health, sex, administration time, administration form, etc., and will be well known to those skilled in the art. Depending on the imaging technique selected, they may vary between 0.001 μg / kg / day and 10,000 mg / kg / day.
[0071] In other embodiments, a triazolo[4,5-d]pyrimidine derivative or a pharmaceutical composition thereof comprising a detectable label and used as a radiotracer may be added to a sample obtained from a host mammal in an amount effective in relation to a selected imaging device.
[0072] A sample obtained from a host mammal means any sampling of cells, tissues or body fluids in which bacterial infection can be determined. Examples of such samples include blood, lymph, urine, biopsy or bone marrow.
[0073] The sample may also refer to an implant, on the surface of which a bacterial infection can be determined.
[0074] Implant means all implanted foreign materials for clinical use in a host mammal, such as for prosthetic joints, pacemakers, implantable cardioverter-defibrillators, intravascular catheters or urinary catheters, stents (including coronary stents), artificial heart valves, intraocular lenses, dental implants, etc.
[0075] In yet another aspect, the present invention also provides a method of imaging a bacterial infection in a host mammal, the method comprising the step of administering to the host mammal a detectable amount of a triazolo[4,5-d]pyrimidine derivative.
[0076] In another aspect, the present invention also provides the use of a triazolo[4,5-d]pyrimidine derivative in an in vitro method for imaging bacterial infection.
[0077] In some embodiments, the method of imaging may include the following steps:
[0078] (a) administering a detectable amount of a triazolo[4,5-d]pyrimidine derivative of formula (1) comprising a detectable marker as described above or a detectable amount of a pharmaceutical composition to a host mammal; or adding a detectable amount of a triazolo[4,5-d]pyrimidine derivative of formula (1) comprising a detectable marker as described above or a detectable amount of a pharmaceutical composition to a sample obtained from a host mammal; and
[0079] (b) tracking the detectable triazolo[4,5-d]pyrimidine derivative by an imaging technique such as, for example, magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), positron emission tomography (PET), positron emission tomography combined with computed tomography, positron emission tomography combined with magnetic resonance imaging;
[0080] And an image of the bacterial infection is displayed.
[0081] In a particular embodiment, the imaging technique is positron emission tomography (PET) or single photon emission computed tomography (SPECT).
[0082] The use of detectable triazolo[4,5-d]pyrimidine derivatives of formula (I) or compositions thereof can be used to indicate bacterial infections, but can also be used to monitor the treatment of bacterial infections in a host. Indeed, by better understanding the severity of bacterial infections, appropriate treatments can be better selected and the potential development of bacterial resistance can be reduced.
[0083] If a detectable triazolo[4,5-d]pyrimidine derivative of formula (I) or a composition thereof is administered or added to a sample obtained from a host prior to treating an infection (eg, by administering an antibiotic), the correct effective amount of the antibiotic will be administered to the host.
[0084] In yet another aspect, the present invention also provides a tracer, preferably a positron emission tomography (PET) tracer or a single photon emission computed tomography (SPECT) tracer, comprising a triazolo[4,5-d]pyrimidine derivative of formula (I), for use in the prognosis and / or diagnosis of bacterial infection in vivo or in the prognosis and / or diagnosis of bacterial infection in vitro.
[0085] In some embodiments, the tracer may be an imaging tracer. In some embodiments, the tracer may include a pharmaceutical composition.
[0086] The invention will now be illustrated with reference to the following figures in the accompanying drawings, which are not intended to limit the scope of the claimed invention:
[0087] Figure 1 shows a reaction scheme illustrating the synthesis of the labeling precursor detailed in step (i) of Example 1; and
[0088] Figure 2 Reaction schemes illustrating the synthesis of other labeling precursors detailed in step (ii) of Example 1 are shown.
[0089] The present invention will be illustrated in more detail in the following examples, which are not intended in any way to limit the scope of the claimed invention.
[0090] Example 1: As a method comprising a detectable marker 18 Triazolo[4,5-d]pyrimidine derivatives of F 18 Preparation of F-Triafluocyl
[0091] i) Figure 1 Synthesis of the first labeling precursor shown: tert-butyl (3-((3aS,4R,6S,6aR)-6-(2-((tert-butoxycarbonyl)oxy)ethoxy)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)((1R,2S)-2-(3-fluoro-4-(trimethylstannyl)phenyl)cyclopropyl)carbamate (5).
[0092] In the first step (i), 2-(((3aR,4S,6R,6aS)-6-((5-amino-6-chloro-2-(propylthio)pyrimidin-4-yl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol (1) is obtained by reaction of 2-(((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol with 4,6-dichloro-2-(propylthio)pyrimidin-5-amine and carried out in acetonitrile at 110° C. in a sealed vessel.
[0093] The next step (ii) consists in the ring closing reaction of intermediate 1 by means of diazotization reaction with sodium nitrite in acetic acid at a temperature of 5°C to 20°C (step ii) to give 2-(((3aR,4S,6R,6aS)-6-(7-chloro-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol (2).
[0094] In step iii, 2-(((3aR,4S,6R,6aS)-6-(7-(((1R,2S)-2-(4-bromo-3-fluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol (3) is obtained by nucleophilic substitution of the chlorine atom of intermediate 2 with 2-(4-bromo-3-fluorophenyl)cyclopropylamine hydrochloride at a temperature of, for example, 20°C.
[0095] Then, after reaction of 3 with di-tert-butyl dicarbonate in tetrahydrofuran at a temperature of, for example, 20° C., the sensitive amino and hydroxyl functions of 3 are protected with tert-butyloxycarbonyl groups (step iv) to give tert-butyl ((1R,2S)-2-(4-bromo-3-fluorophenyl)cyclopropyl)(3-((3aS,4R,6S,6aR)-6-(2-((tert-butoxycarbonyl)oxy)ethoxy)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)carbamate (4).
[0096] In the next step (step v), the labeling position is activated by nucleophilic substitution of the bromine atom of (4) with trimethylstannyl using hexamethyldistannane in the presence of tetrakis(triphenylphosphine)palladium(0) as a catalyst to give tert-butyl (3-((3aS,4R,6S,6aR)-6-(2-((tert-butoxycarbonyl)oxy)ethoxy)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)((1R,2S)-2-(3-fluoro-4-(trimethylstannyl)phenyl)cyclopropyl)carbamate (5).
[0097] Figure 1 The intermediate products (1) to (5) shown are hereinafter referred to as intermediates (1) to (5).
[0098] Intermediate (1) was obtained as follows: a mixture of 4,6-dichloro-2-(propylthio)pyrimidin-5-amine (1.0 g, 4.2 mmol), 2-(((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol (1.17 g, 5.4 mmol) and triethylamine (0.6 mL, 4.2 mmol) in acetonitrile (10 mL) was introduced into a sealed vessel and heated at 110° C. overnight. After evaporation of the solvent, the residue was purified by silica gel column chromatography.
[0099] Yield: 77%.
[0100] Melting point: 112-114℃.
[0101] 1 H NMR(CDCl3)δ1.03(t,J=7.4Hz,3H,SCH2CH2CH3),1.26(s,3H,CH3),1.43(s,3H,CH3),1.75(m,2H,SCH2CH2CH3),1.92(d,J=14.5Hz,1H,5'-Ha),2.2 8(ddd,J=14.5Hz / 5.9Hz / 4.4Hz,1H,5'-Hb),2.59(bs,1H,OH),2.99(ddd,J=13.4Hz / 8.2Hz / 6.4Hz,1H,SCHa),3.14(ddd,J=13.5Hz / 8.2Hz / 6.4Hz,1H ,SCHb),3.38(bs,2H,NH2),3.60(ddd,J=9.9Hz / 6.1Hz / 2.6Hz,1H,OCHa),3.70(ddd,J=9.9Hz / 5.8Hz / 2.5Hz,1H,OCHb),3.79(m,2H,OCH2CH2OH),3.9 7(d,J=4.1Hz,1H,4'-H), 4.53(dd,J=5.4Hz / 1.2Hz,1H,3a'-H), 4.59(m,1H,6'-H), 4.61(dd,J=5.5Hz / 1.8Hz,1H,6a'-H), 6.17(d,J=8.4Hz,1H,NH). 13 C NMR (CDCl3) δ13.5, 23.2, 23.8, 26.2, 32.5, 33.2, 56.8, 61.9, 70.4, 82.8, 84.5, 85.3, 110.3, 116.9, 144.5, 154.4, 162.0.
[0102] Intermediate (2) was obtained as follows: NaNO2 (225 mg, 3.2 mmol) was added to a solution of (1) (1.0 g, 2.4 mmol) in acetic acid (10 mL) cooled on an ice bath. The resulting mixture was allowed to reach room temperature over 1 hour, and then water (40 mL) was added. The resulting mixture was extracted with ethyl acetate (3 x 50 mL), and the combined organic layers were dried with MgSO4 and evaporated to give an oily residue.
[0103] Yield: 94%.
[0104] Melting point: oil.
[0105] 1 H NMR(CDCl3)δ1.09(t,J=7.4Hz,3H,SCH2CH2CH3),1.37(s,3H,CH3),1.55(s,3H,CH3),1.83(h,J= 7.4Hz,2H,SCH2CH2CH3),2.14(t,J=6.0Hz,1H,OH),2.54(m,1H,5'-Ha),2.70(m,1H,5'-Hb),3.21 (t,J=7.2Hz,2H,SCH2CH2CH3),3.49-3.65(m,4H,OCH2CH2OH),4.05(m,1H,4'-H),4.88(d,J=6.3H z,1H,3a'-H),5.21(td,J=7.4Hz / 6.4Hz / 2.5Hz,1H,6'-H),5.53(dd,J=6.3Hz / 2.1Hz,1H,6a'-H). 13 C NMR (CDCl3) δ13.6, 22.3, 24.5, 26.8, 33.9, 35.9, 61.8, 63.4, 70.7, 82.9, 83.6, 84.0, 112.4, 132.2, 150.7, 153.4, 171.8.
[0106] Intermediate (3) was obtained by mixing (2) (0.5 g, 1.16 mmol), 2-(4-bromo-3-fluorophenyl)cyclopropylamine hydrochloride (0.3 g, 1.16 mmol) and triethylamine (0.21 mL, 1.45 mmol) in acetonitrile (10 mL), and reacting the resulting mixture at room temperature for 2 hours. After evaporating the solvent, the residue was purified by silica gel column chromatography.
[0107] Yield: 98%.
[0108] Melting point: 122-124℃.
[0109] 1H NMR (DMSO-d6) δ 0.82 (t, J = 7.4 Hz, 2.4H, SCH2CH2CH3 major), 0.99 (t, J = 7.3 Hz, 0.6H, SCH2CH2CH3 minor), 1.26 (s, 3H, CH3), 1.42 (m, 1H, 3'-Ha), 1.48 (s, 3H, CH3), 1.51 (m, 2H, SCH2CH2CH3 major), 1.59 (dt, J = 10.0 Hz / 5.4 Hz, 1H, 3'-Hb), 1.70 (h, J = 7.3 Hz, 0.4H, SCH 2CH2CH3 minor), 2.14 (ddd, J = 9.6 Hz / 6.4 Hz / 3.3 Hz, 0.8H, 2'-H major), 2.24 (m, 0.2H, 2'-H minor), 2.52 (m, 1H, 5"'-Ha), 2.65 (m, 1H, 5"'-Hb), 2.87 (m, 1.6H, SCH2CH2CH3 major), 3.08 (m, 0.4H, SCH2CH2CH3 minor), 3.19 (dd, J = 7.6 Hz / 4.2 Hz, 0.8H, 1'-H major), 3.39-3.51 (m, 4 H, OCH2CH2OH), 3.75 (m, 0.2H, 1'-H minor), 4.00 (m, 1H, 4"'-H), 4.56 (t, J = 5.2 Hz, 1H, OH), 4.64 (m, 0.2H, 3a"'-H minor), 4.67 (dt, J = 7.0 Hz / 3.3 Hz, 0.8H, 3a"'-H major), 5.01 (m, 1H, 6"'-H), 5.16 (m, 0.2H, 6a"'-H minor), 5.20 (dt, J = 7.3 Hz / 4.8 Hz, 0.8H, 6a"'-H major), 6. 97 (d, J = 7.1 Hz, 0.2H, 6"-H minor), 7.03 (dd, J = 8.3 Hz / 1.9 Hz, 0.8H, 6"-H major), 7.18 (d, J = 10.0 Hz, 0.2H, 2"-H minor), 7.24 (dd, J = 10.4 Hz / 1.9 Hz, 0.8H, 2"-H major), 7.59 (t, J = 7.9 Hz, 1H, 5"-H), 9.01 (d, J = 4.7 Hz, 0.2H, NH minor), 9.41 (dd, J = 3.9 Hz / 1.2 Hz, 0.8H, NH major). 13C NMR(DMSO-d6)δ13.0,15.3,22.3,24.3,24.8,26.9,32.4,34.5,35.4,60.0,61.4,70.7,81.9 ,83.7,104.5,112.5,114.1,123.2,123.9,132.9,144.3,149.1,153.9,157.3,159.3,169.5.
[0110] Intermediate (4) was obtained by mixing (3) (0.62 g, 1.0 mmol), di-tert-butyl dicarbonate (1 g, 4.6 mmol) and 4-(dimethylamino)pyridine (30 mg, cat.) in tetrahydrofuran (10 mL), and reacting the resulting mixture at room temperature overnight. After evaporating the solvent, the residue was purified by silica gel column chromatography.
[0111] Yield: 56%
[0112] Melting point: 156-158℃.
[0113] 1 H NMR(DMSO-d6)δ0.99(td,J=7.3Hz / 2.6Hz,3H,SCH2CH2CH3),1.28(s,3H,CH3),1.35(m,1H,3'-Ha),1.39(s,9H,C(CH3)3),1.40(s,9H,C(CH3)3),1.5 0(s,3H,CH3),1.55(qd,J=7.2Hz / 2.2Hz,1H,3'-Hb),1.70(m,2H,SCH2CH2C H3), 2.26(m, 1H, 2'-H), 2.61(m, 1H, 5"'-Ha), 2.73(m, 1H, 5"'-Hb), 3.05(m , 2H, SCH2CH2CH3), 3.27 (m, 1H, 1'-H), 3.62 (m, 2H, OCH2CH2OC (CH3) 3), 4.04 (m, 3H, OCH2CH2OC (CH3) 3 / 4"'-H), 4.71 (dd, J=7.2Hz / 3.0Hz, 1H, 3a"'-H ),5.15(m,1H,6"'-H),5.27(m,1H,6a"'-H),7.02(dd,J=8.3Hz / 1.9Hz,1H, 6”-H), 7.24(dt,J=10.4Hz / 1.8Hz,1H,2”-H),7.59(t,J=7.9Hz,1H,5”-H). 13C NMR(DMSO-d6)δ13.3,18.1,22.1,24.7,26.0,26.8,27.3,27.4,32.6,35.1,39.0,61.8,65.5,66.7,81.4,82.0,82. 1,82.8,83.6,104.9,112.5,114.7,124.3,127.8,132.9,143.4,150.6,152.3,152.9,154.3,157.2,159.1,169.1.
[0114] Precursor 1: tert-butyl (3-((3aS,4R,6S,6aR)-6-(2-((tert-butoxycarbonyl)oxy)ethoxy)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)((1R,2S)-2-(3-fluoro-4-(trimethylstannyl)phenyl)cyclopropyl)carbamate (5), obtained by mixing (4) (0.41 g, 0.5 mmol), hexamethyldistannane (0.49 g, 1.5 mmol) and tetrakis(triphenylphosphine)palladium(0) (10 mg, cat.) in anhydrous toluene (5 mL), introduced into a sealed container and heated at 100°C overnight under nitrogen. After cooling, ethyl acetate (50 mL) was added and the insoluble matter was filtered off. The filtrate was evaporated to dryness, and the obtained residue was purified by silica gel column chromatography.
[0115] Yield: 65%
[0116] Melting point: 60-62℃.
[0117] 1H NMR(DMSO-d6)δ0.30(s,9H,Sn(CH3)3),0.96(td,J=7.3Hz / 2.9Hz,3H,SCH2CH2CH3),1.28(s,3H,CH3),1.32(m,1H,3'-Ha),1.39(s,9H,C(CH3) 3),1.40(s,9H,C(CH3)3),1.50(m,4H,CH3 / 3'-Hb),1.67(m,2H,SCH2CH2CH3),2.23(m,1H,2'-H),2.58(m,1H,5"'-Ha),2.72(m,1H,5"'-Hb),3 .03(m,2H,SCH2CH2CH3),3.24(m,1H,1'-H),3.61(m,2H,OCH2CH2OC(CH3)3),4.03(m,3H,OCH2CH2OC(CH3)3 / 4"'-H),4.71(d,J=7.1Hz,1H,3a" '-H), 5.15 (t, J = 9.9Hz, 1H, 6"'-H), 5.27 (dt, J = 7.9Hz / 4.4Hz, 1H, 6a"'-H), 6.95 (m, 1H, 2"-H), 7.02 (d, J = 7.4Hz, 1H, 6"-H), 7.59 (m, 1H, 5"-H). 13 C NMR(DMSO-d6)δ-8.9,13.3,17.9,22.1,24.7,26.2,26.8,27.3,27.4,32.6,35.1,39.0,61.8,65.5,66.7,81.4,82.0, 82.1,82.7,83.6,112.1,112.5,122.7,123.6,127.9,136.4,144.2,150.6,152.4,152.9,154.4,166.1,167.9,169.1.
[0118] ii) If Figure 2 Synthesis of other labeled precursors as indicated
[0119] Other precursors can be synthesized from (5) using hydroxy(tosyloxy)iodobenzene (step vi) to give the corresponding iodonium tosylate (6), or from (5) using iodine (step vii) to give (7), followed by addition of Meldrum's acid (step viii) to give the iodonium ylide (8).
[0120] The labeled precursor (6) was obtained by adding hydroxy(tosyloxy)iodobenzene (0.13 g, 0.33 mmol) to a solution of (5) (0.27 g, 0.3 mmol) in dichloromethane (5 mL) at 0° C. After evaporation of the solvent, the residue was purified by silica gel column chromatography.
[0121] Yield: 72%.
[0122] Melting point: 92-95℃.
[0123] 1 H NMR(DMSO-d6)δ0.96(t, J=7.0Hz,3H,SCH2CH2CH3),1.27(s,3H,CH3),1.37(s,9H,C(CH3)3),1.39(s, 9H,C(CH3)3),1.43(m,1H,3'-Ha),1.50(s,3H,CH3),1.63(m,3H,SCH2CH2CH3 / 3'-Hb),2.29(s,3H,CH3 tos ),2.32(m,1H,2'-H),2.57(m,1H,5"'-Ha),2.72(m,1H,5"'-Hb),2.83-3.07(m ,2H,SCH2CH2CH3),3.30(m,1H,1'-H),3.62(m,2H,OCH2CH2OC(CH3)3),4.04(m ,3H,OCH2CH2OC(CH3)3 / 4”'-H),4.70(dd,J=7.2Hz / 2.9Hz,1H,3a”’-H),5.14( m,1H,6"'-H),5.25(dd,J=7.0Hz / 4.6Hz,1H,6a"'-H),7.11(d,J=7.8Hz,2H,3-H tos / 5-H tos ),7.20(dd,J=8.4Hz / 1.7Hz,1H,6”-H),7.41(dd,J=10.0Hz / 1.6Hz,1H,2”-H),7.47(d,J=8.1Hz,2H,2-H tos / 6-H tos ),7.54(t,J=7.8Hz,2H,3””-H / 5””-H),7.68(t,J=7.4Hz,1H,4””-H),8.21(d,J=7.6Hz,2H,2””-H / 6””-H),8.29(dd,J=8.2Hz / 6.6Hz,1H,5””-H). 13C NMR(DMSO-d6)δ13.2,19.0,20.8,22.1,24.7,26.5,26.8,27.3,27.4,32.5,35.2,39.9,61.8,65.5,66.7,81.4,82.0,82.9,83.6,100.3, 112.5,114.5,117.0,125.5,127.8,128.0,131.9,132.2,135.0,136.5,137.5,145.9,150.6,152.2,152.9,154.1,158.3,160.3,169.0.
[0124] The labeled precursor (3-((3aS,4R,6S,6aR)-6-(2-((tert-butoxycarbonyl)oxy)ethoxy)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)((1R,2S)-2-(3-fluoro-4-iodophenyl)cyclopropyl)carbamic acid tert-butyl ester (7) was obtained by adding iodine (0.15 g, 0.6 mmol) to a solution of (5) (0.27 g, 0.3 mmol) in dichloromethane (5 mL). The resulting mixture was reacted at room temperature for 1 hour. After evaporating the solvent, the residue was purified by silica gel column chromatography.
[0125] Yield: 61%.
[0126] Melting point: 151-153℃.
[0127] 1H NMR(DMSO-d6)δ0.98(t,J=7.3Hz,3H,SCH2CH2CH3),1.28(s,3H,CH3),1.34(m,1H,3'-Ha),1.39(s,9H,C(CH3)3),1.40(s,9H,C(CH3)3),1.50(s,3H,C H3),1.53(q,J=6.9Hz,1H,3'-Hb),1.70(h,J=7.3Hz,2H,SCH2CH2CH3),2.2 4(m,1H,2'-H),2.59(m,1H,5"'-Ha),2.72(m,1H,5"'-Hb),3.05(m,2H,SCH2 CH2CH3),3.26(m,1H,1'-H),3.56-3.68(m,2H,OCH2CH2OC(CH3)3),4.03(m,3H,OCH2CH2OC(CH3)3 / 4”'-H),4.70(dd,J=7.2Hz / 3.0Hz,1H,3a”’-H),5.1 5(m,1H,6"'-H),5.26(m,1H,6a"'-H),6.87(dd,J=8.2Hz / 1.8Hz,1H,6"-H) ,7.13(dt,J=9.7Hz / 1.8Hz,1H,2”-H),7.71(dd,J=7.9Hz / 7.1Hz,1H,5”-H). 13 C NMR(DMSO-d6)δ13.3,18.1,22.1,24.7,26.1,26.8,27.3,27.4,31.0,32.6,35.1,39.1,61.9,65.5,66.7,78.3,78.5,81.4, 81.9,82.0,82.7,83.6,112.5,113.7,113.9,124.7,127.9,138.6,144.0,150.6,152.3,152.9,154.3,160.2,162.1,169.1.
[0128] iii) Labeling of precursors 6 and 8 to 18 Conversion of F-Triafluocyl.
[0129] The iodonium groups of both labeling precursors 6 and 8 were converted to 18 F-Triafluocyl:
[0130] Regarding precursor 6, in Makaravagage, Katarina J.; Brooks, Allen F.; Mossine, Andrew V.; Sanford, Melanie S.; Scott, Peter JH, Copper-Mediated Radiofluorination of Arylstannanes with [18F]KF (from Organic Letters (2016), 18(20), 5440-5443).
[0131] Regarding precursor 8, in Rotstein, Benjamin H.; Stephenson, Nickeisha A.; Vasdev, Neil; Liang, Steven H. Spirocyclic hypervalent iodine(III)-mediated radiofluorination of non-activated and hindered aromatics (from Nature Communications (2014), 5, 4365).
[0132] Example 2: In vitro 18 F-Triafluocyl and 18 Comparison of F-FDG uptake assays
[0133] For evaluation 18 To investigate the selective uptake of F-Triafluocyl into bacteria and its utility for the specific diagnosis of bacterial infections, we performed an in vitro assay in which we compared 18 F-triafluocyl and 18 Uptake of F-FDG into bacteria.
[0134] To this end, Staphylococcus epidermidis bacteria were mixed with 18 F-FDG or 18 F-Triafluocyl, and the relative radioactivity associated with the bacterial cells was determined as follows.
[0135] S. epidermidis bacteria were grown overnight in Tryptic Soy Broth (TSB) at 37°C with shaking at 250 rpm. The overnight culture was diluted to an OD of 600 0.1, and incubate until mid-exponential phase is reached. 8The CFU were resuspended in 1 ml of RPMI 1640 cell culture medium provided by Sigma-Aldrich (R7638).
[0136] Bacteria and controls without bacteria were mixed with 2 MBq 18 F-FDG or 2MBq 18 F-Triafluocyl was incubated at 37°C for 1 hour. Bacteria were harvested by centrifugation (600×g, 5 minutes) and washed three times by continuous centrifugation. After washing, cells were transferred to scintillation vials. The supernatant was also collected in a scintillation vial. The cells were counted by a γ counter (2470 Wizard 2TM (Perkin Elmer)) to count bacteria and supernatants.
[0137] Results are obtained in counts / minute. Results were normalized to controls (no bacteria) and by calculating the percentage of activity in scintillation vials containing cells compared to total counts (cells and supernatant combined).
[0138] After incubation with bacteria, we found that 18 The relative activity of F-triafluocyl is 18 The activity of F-FDG is 1.5 to 2 times higher.
[0139] Example 3: In vitro 18 Use of F-Triafluocyl for the prognosis and / or diagnosis of bacterial infection from a blood sample obtained from a host mammal (human).
[0140] Since it is well known in the art that Triafluocyl (also known as Ticagrelor) binds reversibly to the platelet P2Y12 receptor and that platelets accumulate at sites of bacterial infection (as described in Hamzeh-Cognasse H, Damien P, Chabert A, Pozzetto B, Cognasse F, Garraud O. Platelets and infections-complex interactions with bacteria. Front Immunol. 2015; 6:82. Published February 26, 2015. doi: 10.3389 / fimmu.2015.00082), we also compared the uptake of the radiotracer into human platelets in the presence or absence of bacteria.
[0141] Preparation of human washed platelets: Blood samples were collected from healthy volunteers at a volume ratio of 1:6 on acid citrate dextrose (ACD: 93mM Na3-citrate, 7mM citric acid, 14mM glucose, pH 6.0) containing 1U / ml apyrase. The blood was centrifuged at 800×g for 5 seconds and then at 100×g for 5 minutes to obtain platelet-rich plasma (PRP). PRP was diluted 3-fold in ACD containing 1U / ml apyrase ((apyrase from potato, grade I (A6132 Sigma-Aldrich)) and centrifuged at 1000×g to obtain platelet pellets. The platelet pellets were centrifuged at 3×10 8 ml -1 The concentration was resuspended in Tyrode's buffer (137 mM NaCl, 12 mM NaHCO3, 2 mM KCl, 0,34 mM Na2HPO4, 1 mM MgCl2, 5.5 mM glucose, 5 mM Hepes, 0.35% bovine serum albumin from Sigma Aldrich A3294), and Hepes refers to 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid, N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (H4034, Sigma-Aldrich).
[0142] Bacteria, platelets, and controls without bacteria were mixed with 2MBq 18 F-FDG or 2MBq 18 F-Triafluocyl was incubated at 37°C for 1 hour. Bacteria and platelets were harvested by centrifugation (1000×g, 10 minutes) and washed three times by continuous centrifugation (1000×g, 10 minutes). The supernatant was collected in a scintillation bottle. After washing, the cells were transferred to a scintillation bottle. The cells were counted by a γ counter (2470 Wizard 2TM (Perkin Elmer)) to count cells and supernatants.
[0143] Results are obtained in counts / minute. Results were normalized to control (no cells) and by calculating the percentage of activity in scintillation vials containing cells compared to total counts (cells and supernatant combined).
[0144] The results confirmed 18 F-triafluocyl is taken up into platelets, and 18 F-FDG was not transported into these cells. Furthermore, after incubation with platelet suspensions containing bacteria, we found that 18 The relative activity of F-triafluocyl is 18The activity of F-FDG is about 10 times higher.
[0145] Embodiment 4: 18 Selective use of F-Triafluocyl for the prognosis and / or diagnosis of bacterial infections on mammalian cells obtained from human hosts
[0146] S. epidermidis bacteria were grown overnight in Tryptic Soy Broth (TSB) at 37°C with shaking at 250 rpm. The overnight culture was diluted to an OD of 600 0.1, and incubate until mid-exponential phase is reached. 8 CFU were resuspended in 1 ml RPMI 1640.
[0147] THP1( TIB-202 TM) and HL60( CCL-240 TM) The cell lines were grown at 37°C and 5% CO2 in RPMI 1640 tissue culture medium supplemented with L-glutamine, 10% fetal bovine serum and 1% penicillin / streptomycin. HTB-38) were grown at 37°C and 5% CO2 in McCoy's 5A medium and 10% fetal bovine serum.
[0148] Harvest non-adherent cell lines (HL60, THP1; 1×10 6 Cells ml -1 ), washed, and resuspended in 1 ml tissue culture medium. Adherent HT29 cells were maintained in 6-well plates at 80% confluence.
[0149] Bacteria, cell lines, and controls without cells were co-cultured with 2MBq 18 F-FDG or 2MBq 18 F-ticagrelor was incubated at 37°C for 1 hour. Bacteria and non-adherent cells were harvested by centrifugation (600×g, 5 minutes) and washed three times by continuous centrifugation. The cell supernatant was collected in a scintillation bottle. After washing, the cells were transferred to a scintillation bottle. The adherent cells were washed three times with fresh culture medium (McCoy's 5A culture medium plus 10% fetal bovine serum). The supernatant was collected in a scintillation bottle. The adherent cells were separated by trypsin treatment and placed in a scintillation bottle. The scintillation bottles for cells and supernatants were counted by a γ counter. The results were obtained in counts / minute. The results were standardized for the control (no cells) and by calculating the percentage of activity in the scintillation bottles containing cells compared to the total count (cells and supernatant combined).
[0150] The results confirmed 18F-Triafluocyl was uptaken into bacteria, while no uptake was observed in any mammalian cells, leukocytes (THP1 and HL-60), or tumor (HT29) cells. In contrast, we observed 18 F-FDG uptake into three mammalian cell lines. 18 F-Triafluocyl can be used for specific in vitro detection of bacterial infections in human samples.
[0151] Example 5: In vivo prognostic and / or diagnostic protocols
[0152] Test protocols have been established for the in vivo prognosis and / or diagnosis of bacterial infections in patients and are suitable for use 18 F-Triafluocyl was used as a radioactive tracer.
[0153] The protocol below was developed for PET-CT imaging, but can be easily extrapolated to other imaging techniques such as SPECT by one skilled in the art.
[0154] The protocol is based on identical image acquisition for each patient:
[0155] After fasting for at least 6 hours, 3.7 MBq was injected via a peripheral intravenous catheter 18 F-Triafluocyl / Kg body weight (average activity / patient: 277MBq, range: 202-394MBq). Patients were placed in a quiet room and instructed not to move. About 1 hour after injection of 18F-Triafluocyl (average: 69 minutes, range: 54-100 minutes), a static whole body examination was performed with a PET-CT scanner. Volumetric low-dose axial CT images were obtained. Then, emission raw data images were recorded at each bed position and reconstructed into overlapping coronal slices after scatter correction (convolution subtraction) and normalization correction based on the CT attenuation model.
[0156] This protocol can be applied to patients with bacterial infections, allowing deep localization in all tissues of the patient's body such as muscle, epithelium, connective tissue and nerves, while patients with cancer or sterile inflammation are not easily detected by this protocol.
Claims
1. A use of a triazolo[4,5-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a tracer for use in the diagnosis of bacterial infection in a host mammal and further comprising a detectable marker or in combination with a detectable marker, Where R 1 is C optionally substituted by one or more halogen atoms 3-5 Alkyl; R 2 is phenyl optionally substituted by one or more halogen atoms; R 3 and R 4 Each is hydroxy; R is XOH, wherein X is CH2, OCH2CH2 or a bond; Provided that when X is CH2 or a bond, R 1 is not propyl; when X is CH2 and R 1 When it is CH2CH2CF3, butyl or pentyl, R 2 The phenyl group at the position must be substituted by fluorine; when X is OCH2CH2 and R 1 When it is propyl, R 2 The phenyl group at the wherein the detectable marker is 18 F.
2. The use according to claim 1, wherein R 2 It is a phenyl group substituted by a fluorine atom.
3. The method according to claim 1, wherein R is OH or OCH2CH2OH.
4. The use according to claim 1, wherein R is OH.
5. The use according to claim 1, wherein the triazolo[4,5-d]pyrimidine derivative or a pharmaceutically acceptable salt thereof is selected from: (1R-(1α,2α,3β(1R*,2*),5β))-3-(7-((2-(3,4-difluorophenyl)cyclopropyl)amino)-5-((3,3,3-trifluoropropyl)thio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(hydroxy)cyclopentane-1,2-diol; (1S-(1α,2α,3β(1R*,2*),5β))-3-(7-((2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol); (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(4-fluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol); 1S,2R,3S,4R)-4-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-1,2,3-cyclopentanetriol; or a pharmaceutically acceptable salt thereof.
6. The use according to claim 1, which is (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol, also known as Triafluocyl).
7. The use according to claim 1, which is 1S,2R,3S,4R)-4-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-1,2,3-cyclopentanetriol, also known as Fluometacyl.
8. The use according to claim 1, wherein the bacterial infection is caused by one or more bacteria selected from the group consisting of Staphylococcus aureus (S. aureus), Staphylococcus epidermidis (S. epidermidis), Enterococcus faecalis (E. faecalis), Enterococcus faecium (E. faecium), coagulase-negative Staphylococci (CoNS), vancomycin-resistant enterococci (VRE), β-hemolytic Streptococcus agalactiae (Streptococcus agalactiae) or other streptococci.
9. The use according to claim 1, wherein the bacterial infection is caused by methicillin-resistant Staphylococcus aureus (MRSA).
10. The use according to claim 1, wherein the bacterial infection is caused by methicillin-resistant Staphylococcus epidermidis (MRSE).
11. The use according to claim 1, wherein the bacterial infection is caused by glycopeptide-intermediately resistant Staphylococcus aureus (GISA).
12. The use according to claim 1, wherein the bacterial infection is caused by one or more bacteria selected from the group consisting of Acinetobacter baumannil, Pseudomonas aeruginosa and Enterobacteriaceae.
13. The use according to claim 1, wherein the bacterial infection is caused by carbapenem-resistant Pseudomonas aeruginosa.
14. The use according to claim 1, wherein the bacterial infection is caused by third generation cephalosporin-resistant Enterobacteriaceae.
15. The use according to claim 1, wherein the bacterial infection is caused by one or more bacteria selected from the group consisting of Klebsiella pneumonia, Enterobacter spp, Serratia spp, Proteus spp, Providentia spp and Morganella spp.
16. The use according to claim 1, wherein the bacterial infection is caused by Escherichia coli.
17. Use of a pharmaceutical composition for the preparation of a tracer for diagnosing in vivo bacterial infection in a host mammal, the pharmaceutical composition comprising a triazolo[4,5-d]pyrimidine derivative of formula (I) as defined in any one of claims 1 to 7 and a pharmaceutically acceptable additive.
18. Use of a triazolo[4,5-d]pyrimidine derivative of formula (I) as defined in any one of claims 1 to 7 or a pharmaceutical composition as defined in claim 17 in the preparation of a tracer for imaging a bacterial infection in a host mammal by imaging techniques to display the bacterial infection 19. The use according to claim 18, wherein the imaging technique is magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), computed tomography (CT), single photon emission computed tomography (SPECT) together with computed tomography (CT), positron emission tomography imaging (PET), positron emission tomography together with computed tomography (CT) imaging, positron emission tomography together with magnetic resonance imaging or ultrasound imaging (US).
20. The use according to claim 18 or 19, wherein the bacterial infection is caused by one or more bacteria selected from the group consisting of Staphylococcus aureus (S. aureus), Staphylococcus epidermidis (S. epidermidis), Enterococcus faecalis (E. faecalis), Enterococcus faecium (E. faecium), coagulase-negative Staphylococci (CoNS), vancomycin-resistant enterococci (VRE), β-hemolytic Streptococcus agalactiae (Streptococcus agalactiae) or other streptococci.
21. The use according to claim 18 or 19, wherein the bacterial infection is caused by methicillin-resistant Staphylococcus aureus (MRSA).
22. The use according to claim 18 or 19, wherein the bacterial infection is caused by methicillin-resistant Staphylococcus epidermidis (MRSE).
23. The use according to claim 18 or 19, wherein the bacterial infection is caused by glycopeptide-intermediately resistant Staphylococcus aureus (GISA).
24. The use according to claim 18 or 19, wherein the bacterial infection is caused by one or more bacteria selected from the group consisting of Acinetobacter baumannil, Pseudomonas aeruginosa and Enterobacteriaceae.
25. The use according to claim 18 or 19, wherein the bacterial infection is caused by carbapenem-resistant Pseudomonas aeruginosa.
26. The use according to claim 18 or 19, wherein the bacterial infection is caused by 3rd generation cephalosporin-resistant Enterobacteriaceae.
27. The use according to claim 18 or 19, wherein the bacterial infection is caused by one or more bacteria selected from the group consisting of Klebsiella pneumonia, Enterobacter spp, Serratia spp, Proteus spp, Providentia spp and Morganella spp.
28. The use according to claim 18 or 19, wherein the bacterial infection is caused by Escherichia coli.
